You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,343,927


✉ Email this page to a colleague

« Back to Dashboard


Title:Pharmaceutical compositions for prevention of overdose or abuse
Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
Inventor(s): Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Lauderback; Christopher (Blacksburg, VA)
Assignee: Shire LLC (Florence, KY)
Filing Date:Sep 13, 2010
Application Number:12/881,008
Claims:1. A method of treating attention deficit hyperactivity disorder in a patient in need thereof, comprising orally administering an effective amount of an amphetamine (1-phenylpropan-2-amine) covalently bound to a chemical moiety, wherein the chemical moiety is a naturally occurring, non-standard amino acid, the amino acid is bound through its C-terminus to the amino group of the amphetamine, and the bound amphetamine maintains a steady-state serum release curve which provides a therapeutically effective bioavailability of the amphetamine.

2. The method of claim 1, wherein the naturally occurring, non-standard amino acid is homoserine.

3. The method of claim 1, wherein the naturally occurring, non-standard amino acid is ornithine.

4. The method of claim 1, wherein the naturally occurring, non-standard amino acid is sarcosine.

5. The method of claim 1, wherein the amphetamine is dextroamphetamine.

6. A method of treating attention deficit hyperactivity disorder in a patient in need thereof, comprising orally administering an effective amount of an amphetamine (1-phenylpropan-2-amine) covalently bound to a chemical moiety, wherein the chemical moiety is a naturally occurring, non-standard amino acid and the amino acid is bound through its C-terminus to the amino group of the amphetamine, wherein the bound amphetamine is administered in an oral dosage form.

7. The method of claim 6, wherein the amphetamine is dextroamphetamine.

8. The method of claim 6, wherein the oral dosage form comprises from 5 to 500 mg of the bound amphetamine.

9. The method of claim 6, wherein the patient is administered an oral dosage form of the bound amphetamine once daily.

10. The method of claim 7, wherein the oral dosage form comprises from 5 to 500 mg of the bound amphetamine.

11. The method of claim 7, wherein the patient is administered an oral dosage form of the bound amphetamine once daily.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.